Product Name: Acetylated Lysine
Product Number: AB-NN135-2
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Acetylated Lysine
Target Alias: Acetyl Lysine
Product Type Specific: Acetylated lysine-specific pan-specific antibody
Antibody Code: NN135-2
Antibody Target Type: Pan-specific
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG1
Antibody Immunogen Source: Acetylated KLH
Production Method: Protein G purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Target Alias: Acetyl Lysine
Product Type Specific: Acetylated lysine-specific pan-specific antibody
Antibody Code: NN135-2
Antibody Target Type: Pan-specific
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG1
Antibody Immunogen Source: Acetylated KLH
Production Method: Protein G purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH7.4, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:1000); optimal dilutions for assays should be determined by the user.
Antibody Potency: Medium-high potency. Detects proteins containing acetylated lysine residues in ELISA and Western blots.
Storage Buffer: Phosphate buffered saline pH7.4, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:1000); optimal dilutions for assays should be determined by the user.
Antibody Potency: Medium-high potency. Detects proteins containing acetylated lysine residues in ELISA and Western blots.
Antibody Species Reactivity: Species Independent. Bovine albumin and avian histones were tested.
Antibody Positive Control: 1µg of SMC-153 was sufficient to detect acetylated chicken erythrocyte histones (sodium butyrate-treated) using 20 µg total protein, on western blot by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Very high
Antibody Cross Reactivity: Does not detect non-acetylated lysine residues.
Related Product 1: Acetylated lysine pan-specific antibody (Cat. No.: AB-NN135-1)
Antibody Positive Control: 1µg of SMC-153 was sufficient to detect acetylated chicken erythrocyte histones (sodium butyrate-treated) using 20 µg total protein, on western blot by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Very high
Antibody Cross Reactivity: Does not detect non-acetylated lysine residues.
Related Product 1: Acetylated lysine pan-specific antibody (Cat. No.: AB-NN135-1)
Scientific Background: Post-translational modifications of proteins play critical roles in the regulation and function of many known biological processes. Proteins can be post-translationally modified in many different ways, and a common post-transcriptional modification of Lysine involves acetylation (1). The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (2). Protein posttranslational reversible lysine Nε development (5).
References
[1] Yang XJ. (2005). Oncogene. 24:1653-1662.
[2] Hassig, C.A. and Schreiber, S.L. (1997). Curr. Opin. Chem. Biol. 1(3): 300-308.
[4] Yang XJ. (2004). Bioessays 26:1076-1087.
[5] Hughes, R.E. (2002). Curr. Biol. 12: R141-R143.
[6] Vigushin, D.M. and Coombes, R.C. (2004). Curr. Cancer Drug Targets 4: 205-218.
[1] Yang XJ. (2005). Oncogene. 24:1653-1662.
[2] Hassig, C.A. and Schreiber, S.L. (1997). Curr. Opin. Chem. Biol. 1(3): 300-308.
[4] Yang XJ. (2004). Bioessays 26:1076-1087.
[5] Hughes, R.E. (2002). Curr. Biol. 12: R141-R143.
[6] Vigushin, D.M. and Coombes, R.C. (2004). Curr. Cancer Drug Targets 4: 205-218.
© Kinexus Bioinformatics Corporation 2017